Inhibrx Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	0.2	1.8	1.32
Revenue Growth (YoY)	-88.89%	36.88%	-
Cost of Revenue	203.74	191.64	101.6
Gross Profit	-203.54	-189.84	-100.29
Selling, General & Admin	59.84	29.35	15.04
Operating Expenses	59.84	29.35	15.04
Operating Income	-263.39	-219.19	-115.32
Interest Expense	-13.49	-31.84	-
Interest & Investment Income	10.94	11.92	-
Earnings From Equity Investments	-	-1.63	-
Other Non Operating Income (Expenses)	0.08	-0.58	0
EBT Excluding Unusual Items	-265.86	-241.32	-115.32
Merger & Restructuring Charges	-68.06	-0.04	-
Other Unusual Items	2,021	-	-
Pretax Income	1,688	-241.36	-115.32
Income Tax Expense	0	0	0
Net Income	1,688	-241.36	-115.33
Net Income to Common	1,688	-241.36	-115.33
Shares Outstanding (Basic)	15	12	-
Shares Outstanding (Diluted)	15	12	-
Shares Change (YoY)	27.17%	-	-
EPS (Basic)	114.01	-20.48	-
EPS (Diluted)	112.62	-20.48	-
Free Cash Flow	-197.01	-197.9	-91.5
Free Cash Flow Per Share	-13.15	-16.80	-
Operating Margin	-131693.50%	-12176.94%	-8769.81%
Profit Margin	843786.00%	-13408.94%	-8769.96%
Free Cash Flow Margin	-98503.00%	-10994.56%	-6957.95%
EBITDA	-261.1	-217.99	-114.1
D&A For EBITDA	2.29	1.19	1.23
EBIT	-263.39	-219.19	-115.32
Revenue as Reported	0.2	1.8	1.32

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q